HOME >> MEDICINE >> NEWS
Drug to block mother-to-child HIV transmission induces resistance more often than previously thought

The incidence of drug resistance associated with single-dose nevirapine, a drug used to prevent mother-to-child transmission of HIV-1, may be substantially higher than previously thought and of particular risk for those infected with HIV-1 subtype C, according to three new studies published in the July 1 issue of The Journal of Infectious Diseases, now available online.

A single dose of nevirapine given to an HIV-infected pregnant woman during delivery, and another given to her newborn, can cut the rate of mother-to-child HIV transmission in half. The relative simplicity and affordability of single-dose nevirapine have made it the drug of choice for prevention of mother-to-child transmission in many developing countries.

This new research expands understanding of the risks of drug resistance associated with single-dose nevirapine, but as noted by all three research groups, the clinical implications for patients are not yet clear. More research will be needed to determine whether nevirapine used to prevent mother-to-child transmission affects the chances of successful treatment later with nonnucleoside reverse transcriptase inhibitors, the class of drug to which nevirapine belongs.

Two of the studies analyzed the incidence of nevirapine-associated resistance using laboratory tests more sensitive than standard genotypic assays. In the first, researchers led by Jeffrey A. Johnson, PhD, of the Centers for Disease Control and Prevention, used a new, very sensitive technique to detect resistance mutations in samples of HIV-1 obtained from 50 South African women before and after treatment with single-dose nevirapine. Using a less-sensitive conventional technique called sequence analysis, researchers had previously estimated that viral resistance to nevirapine emerged in approximately 40 percent of women after receiving the single-dose therapy. In contrast, Dr. Johnson and colleagues concluded that resistance emerges in at least 65 percent of women a
'"/>

Contact: Steve Baragona
sbaragona@idsociety.org
703-299-0412
Infectious Diseases Society of America
1-Jun-2005


Page: 1 2 3

Related medicine news :

1. Scientists train nano-building blocks to take on new shapes, as reported in Science
2. Future therapies for stroke may block cell death
3. Scavenger cells may have role blocking obesity, Stanford study shows
4. Computer scientist reveals the math and science behind blockbuster movies
5. First-degree fetal heart block may be reversible
6. MR angiography highly accurate in detecting blocked arteries
7. Scientists stop colon cancer growth in mice by blocking just one enzyme
8. A world first in the treatment of a young patient with a completely blocked yet vital heart artery
9. People often forgo using lifesaving beta blockers despite health insurance
10. Drug could change the standard treatment during procedures to clear blocked arteries
11. Tumor necrosis factor blockers may not cause cancer after all

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... ... March 23, 2017 , ... Altec ... The Resource Group as their 2016 Microsoft Dynamics Partner of the Year at ... CA. The award recognizes The Resource Group for their outstanding relationship with ...
(Date:3/23/2017)... ... March 23, 2017 , ... ChenMed, ... announced rapid completion of the strategic executive team expansion needed to further optimize ... the ChenMed executive team,” says Christopher Chen, MD, ChenMed Chief Executive Officer. ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... According to ... Americans, yet poor sleep is likely not the only cause of the sunken-eye look, ... that make you look older or in poor health are likely due to genetics, ...
(Date:3/23/2017)... PA (PRWEB) , ... March 23, 2017 , ... It’s ... That means many students are thinking about summer internships , which can be ... thereof). , The pros at Garden Media Group, a boutique public relations firm outside ...
(Date:3/23/2017)... ... March 23, 2017 , ... Corra Group is now ... pricing. Verisys through its FACIS and other services maintains the largest ... , “We are delighted to be able to offer these various products to ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company ... unmet medical needs in rare diseases, today announced that ... on Monday, April 3 during ENDO 2017, the annual ... Florida , to discuss new data regarding its ... PTH and TransCon CNP). Ascendis is presenting ...
(Date:3/23/2017)... -- Prima BioMed has presented encouraging early ... in combination with Keytruda, with one of the six ... complete response. Recruitment in the second cohort is complete ... recruited by Q317. Preliminary efficacy data from the 15-patient, ... expected mid-year (recruitment in the 226-patient Phase IIb component ...
(Date:3/23/2017)... Piramal Pharma Solutions (PPS), ... nombramiento de Stuart E. Needleman como ... integrados completa para su base de clientes farmacéuticos ... el crecimiento y ejecución de las ofertas PPS. ... todas las actividades de desarrollo empresarial global para ...
Breaking Medicine Technology:
Cached News: